Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ruxolitinib in Combination With Corticosteroid as First Line Therapy for the Treatment of High Risk Acute Graft-Versus-Host Disease

NCT04061876 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.

NCT NCT04061876
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04061876 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ruxolitinib in Combination With Corticosteroid as First Line Therapy for the Treatment of High Risk Acute Graft-Versus-Host Disease
Lead sponsor
Chinese PLA General Hospital
Phase
Phase 2
Overall status
Completed
Start date
August 25, 2019
Completion date
June 30, 2023
Enrollment
198 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

agvhd, stem cell transplant complications